These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 39339943)

  • 1. The Synergistic Effect of Baloxavir and Neuraminidase Inhibitors against Influenza Viruses In Vitro.
    Guo X; Zhao L; Li W; Cao R; Zhong W
    Viruses; 2024 Sep; 16(9):. PubMed ID: 39339943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In Vitro Combinations of Baloxavir Acid and Other Inhibitors against Seasonal Influenza A Viruses.
    Checkmahomed L; Padey B; Pizzorno A; Terrier O; Rosa-Calatrava M; Abed Y; Baz M; Boivin G
    Viruses; 2020 Oct; 12(10):. PubMed ID: 33049959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Duration of fever in children infected with influenza A(H1N1)pdm09, A(H3N2) or B virus and treated with baloxavir marboxil, oseltamivir, laninamivir, or zanamivir in Japan during the 2012-2013 and 2019-2020 influenza seasons.
    Sun Y; Wagatsuma K; Saito R; Sato I; Kawashima T; Saito T; Shimada Y; Ono Y; Kakuya F; Minato M; Kodo N; Suzuki E; Kitano A; Chon I; Phyu WW; Li J; Watanabe H
    Antiviral Res; 2024 Aug; 228():105938. PubMed ID: 38897317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2017-2018.
    Takashita E; Daniels RS; Fujisaki S; Gregory V; Gubareva LV; Huang W; Hurt AC; Lackenby A; Nguyen HT; Pereyaslov D; Roe M; Samaan M; Subbarao K; Tse H; Wang D; Yen HL; Zhang W; Meijer A
    Antiviral Res; 2020 Mar; 175():104718. PubMed ID: 32004620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fitness of influenza A and B viruses with reduced susceptibility to baloxavir: A mini-review.
    Abed Y; Saim-Mamoun A; Boivin G
    Rev Med Virol; 2021 May; 31(3):e2175. PubMed ID: 32975358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Susceptibility of Influenza A, B, C, and D Viruses to Baloxavir
    Mishin VP; Patel MC; Chesnokov A; De La Cruz J; Nguyen HT; Lollis L; Hodges E; Jang Y; Barnes J; Uyeki T; Davis CT; Wentworth DE; Gubareva LV
    Emerg Infect Dis; 2019 Oct; 25(10):1969-1972. PubMed ID: 31287050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic activity of an RNA polymerase PA-PB1 interaction inhibitor with oseltamivir against human and avian influenza viruses in cell culture and in ovo.
    Bonomini A; Zhang J; Ju H; Zago A; Pacetti M; Tabarrini O; Massari S; Liu X; Mercorelli B; Zhan P; Loregian A
    Antiviral Res; 2024 Oct; 230():105980. PubMed ID: 39117284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baloxavir marboxil: the new influenza drug on the market.
    O'Hanlon R; Shaw ML
    Curr Opin Virol; 2019 Apr; 35():14-18. PubMed ID: 30852344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baloxavir treatment of ferrets infected with influenza A(H1N1)pdm09 virus reduces onward transmission.
    Lee LYY; Zhou J; Frise R; Goldhill DH; Koszalka P; Mifsud EJ; Baba K; Noda T; Ando Y; Sato K; Yuki AI; Shishido T; Uehara T; Wildum S; Zwanziger E; Collinson N; Kuhlbusch K; Clinch B; Hurt AC; Barclay WS
    PLoS Pathog; 2020 Apr; 16(4):e1008395. PubMed ID: 32294137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genotypic and phenotypic susceptibility of emerging avian influenza A viruses to neuraminidase and cap-dependent endonuclease inhibitors.
    Andreev K; Jones JC; Seiler P; Kandeil A; Webby RJ; Govorkova EA
    Antiviral Res; 2024 Sep; 229():105959. PubMed ID: 38986873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Comparison of the Frequency of Prescription and Pharmacy Revisits between Baloxavir Marboxil and Neuraminidase Inhibitors in Influenza-Infected Pediatric Patients during the 2019-2020 Influenza Season.
    Norikoshi Y; Ikeda T; Sasahara K; Hamada M; Torigoe E; Nagae M; Tashiro T; Horio F; Saruwatari J; Uchida Y; Anraku M
    Biol Pharm Bull; 2020; 43(12):1960-1965. PubMed ID: 33268716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of influenza A(H3N2) viruses with polymerase acidic subunit substitutions after and prior to baloxavir marboxil treatment during the 2022-2023 influenza season in Japan.
    Chon I; Wagatsuma K; Saito R; Tang JW; Isamu S; Suzuki E; Shirahige Y; Kawashima T; Minato M; Kodo N; Masaki H; Hamabata H; Yoshioka S; Ichikawa Y; Sun Y; Li J; Otoguto T; Watanabe H
    Antiviral Res; 2024 Sep; 229():105956. PubMed ID: 38969237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Baloxavir and Oseltamivir in Combination on Infection with Influenza Viruses with PA/I38T or PA/E23K Substitutions in the Ferret Model.
    Koszalka P; George A; Dhanasekaran V; Hurt AC; Subbarao K
    mBio; 2022 Aug; 13(4):e0105622. PubMed ID: 35938724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influenza A(H1N1)pdm09 virus exhibiting reduced susceptibility to baloxavir due to a PA E23K substitution detected from a child without baloxavir treatment.
    Takashita E; Abe T; Morita H; Nagata S; Fujisaki S; Miura H; Shirakura M; Kishida N; Nakamura K; Kuwahara T; Mitamura K; Ichikawa M; Yamazaki M; Watanabe S; Hasegawa H;
    Antiviral Res; 2020 Aug; 180():104828. PubMed ID: 32574689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baloxavir Marboxil: A Review in Acute Uncomplicated Influenza.
    Shirley M
    Drugs; 2020 Jul; 80(11):1109-1118. PubMed ID: 32601915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the Baloxavir-Resistant Polymerase Acid I38T Substitution on the Fitness of Contemporary Influenza A(H1N1)pdm09 and A(H3N2) Strains.
    Checkmahomed L; M'hamdi Z; Carbonneau J; Venable MC; Baz M; Abed Y; Boivin G
    J Infect Dis; 2020 Jan; 221(1):63-70. PubMed ID: 31419295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of contemporary influenza B recombinant viruses harboring mutations of reduced susceptibility to baloxavir marboxil, in vitro and in mice.
    Abed Y; Fage C; Checkmahomed L; Venable MC; Boivin G
    Antiviral Res; 2020 Jul; 179():104807. PubMed ID: 32343991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuraminidase inhibitors and single dose baloxavir are effective and safe in uncomplicated influenza: a meta-analysis of randomized controlled trials.
    Tejada S; Tejo AM; Peña-López Y; Forero CG; Corbella X; Rello J
    Expert Rev Clin Pharmacol; 2021 Jul; 14(7):901-918. PubMed ID: 33861168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016/17 and 2017/18 seasons.
    Gubareva LV; Mishin VP; Patel MC; Chesnokov A; Nguyen HT; De La Cruz J; Spencer S; Campbell AP; Sinner M; Reid H; Garten R; Katz JM; Fry AM; Barnes J; Wentworth DE
    Euro Surveill; 2019 Jan; 24(3):. PubMed ID: 30670144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuraminidase inhibitor susceptibility surveillance of influenza viruses circulating worldwide during the 2011 Southern Hemisphere season.
    Okomo-Adhiambo M; Sleeman K; Lysén C; Nguyen HT; Xu X; Li Y; Klimov AI; Gubareva LV
    Influenza Other Respir Viruses; 2013 Sep; 7(5):645-58. PubMed ID: 23575174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.